The Potential of RNA Exon Editing with Ascidian Therapeutics' Romesh Subramanian, Ph.D.

<p><em>Cell &amp; Gene: The Podcast</em> Host, Erin Harris, welcomes Romesh Subramanian, Ph.D., CEO of Ascidian Therapeutics, a Boston-based biotech focused on rewriting RNA to the pod. During the episode, Subramanian defines RNA exon editing, and they discuss the differences between RNA exon editing and gene editing. With current programs in ophthalmology, neurological and neuromuscular disorders, as well as rare diseases, Subramanian explains the overwhelming potential of RNA exon editing. </p>